Eli Lilly and Company (Lilly) and AC Immune have signed a license and collaboration agreement, potentially worth around CHF1.89bn ($1.9bn), for research and development of tau aggregation inhibitor small molecules for the treatment of neurodegenerative diseases like Alzheimer’s disease (AD).
AMAG Pharmaceuticals has signed an agreement to acquire US-based private biopharmaceutical firm Perosphere Pharmaceuticals.
X-Chem and Almirall have partnered to discover lead compounds for innovative and challenging targets with dermatology applications.
Researchers at the Weizmann Institute of Science in Israel have revealed a previously unknown mechanism underlying anxiety.
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.
Versant Ventures, through a $20m Series A financing, has launched Black Diamond Therapeutics, a biotechnology company focused on developing a new type of precision medicine for cancer.
e-therapeutics has entered into a research collaboration with Danish drug manufacturer Novo Nordisk to discover biological mechanisms and therapies to treat type-2 diabetes.
UK-based clinical-stage biopharmaceutical firm Mereo BioPharma Group and oncology-focused clinical stage biopharmaceutical business OncoMed Pharmaceuticals have agreed to merge.
Global biopharmaceutical company UCB is investing around £1bn in the UK for research and development, supporting the country’s life sciences sector.
Alphabet-owned DeepMind has claimed that research powered by artificial intelligence (AI) can help to predict the 3D structure of a protein on just its genetic sequence.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.